Logo image of ALERS.PA

EUROBIO-SCIENTIFIC (ALERS.PA) Stock Price, Forecast & Analysis

Europe - EPA:ALERS - FR0013240934 - Common Stock

24.2 EUR
-0.3 (-1.22%)
Last: 11/11/2025, 7:00:00 PM

ALERS.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap248.05M
Revenue(TTM)162.09M
Net Income(TTM)2.36M
Shares10.25M
Float800.00K
52 Week High26.5
52 Week Low21.8
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.23
PE105.22
Fwd PE20.79
Earnings (Next)04-06 2026-04-06
IPO2005-11-18
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ALERS.PA short term performance overview.The bars show the price performance of ALERS.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -1 -2 -3 -4

ALERS.PA long term performance overview.The bars show the price performance of ALERS.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 20 30 40

The current stock price of ALERS.PA is 24.2 EUR. In the past month the price decreased by -2.42%. In the past year, price decreased by -6.02%.

EUROBIO-SCIENTIFIC / ALERS Daily stock chart

ALERS.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ARGX.BR ARGENX SE 72.44 47.90B
1AE.DE ARGENX SE 69.42 45.91B
22UA.DE BIONTECH SE-ADR N/A 23.30B
2X1.DE ABIVAX SA N/A 7.01B
ABVX.PA ABIVAX SA N/A 7.09B
GLPG.AS GALAPAGOS NV N/A 1.86B
5CV.DE CUREVAC NV 5.19 1.02B
NANO.PA NANOBIOTIX N/A 889.09M
PHIL.MI PHILOGEN SPA 20.53 684.22M
IVA.PA INVENTIVA SA N/A 489.36M
FYB.DE FORMYCON AG N/A 384.32M
VLA.PA VALNEVA SE N/A 335.76M

About ALERS.PA

Company Profile

ALERS logo image Eurobio-Scientific SA provides in vitro diagnostics solutions. The company is headquartered in Les Ulis, Ile-De-France and currently employs 380 full-time employees. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.

Company Info

EUROBIO-SCIENTIFIC

ZA de Courtaboeuf 7 Avenue de Scandinavie, Les Ulis Cedex

Les Ulis ILE-DE-FRANCE FR

Employees: 329

ALERS Company Website

ALERS Investor Relations

Phone: 331169796480

EUROBIO-SCIENTIFIC / ALERS.PA FAQ

What does EUROBIO-SCIENTIFIC do?

Eurobio-Scientific SA provides in vitro diagnostics solutions. The company is headquartered in Les Ulis, Ile-De-France and currently employs 380 full-time employees. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.


Can you provide the latest stock price for EUROBIO-SCIENTIFIC?

The current stock price of ALERS.PA is 24.2 EUR. The price decreased by -1.22% in the last trading session.


What is the dividend status of EUROBIO-SCIENTIFIC?

ALERS.PA does not pay a dividend.


How is the ChartMill rating for EUROBIO-SCIENTIFIC?

ALERS.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Can you provide the PE ratio for ALERS stock?

The PE ratio for EUROBIO-SCIENTIFIC (ALERS.PA) is 105.22. This is based on the reported non-GAAP earnings per share of 0.23 and the current share price of 24.2 EUR.


Would investing in EUROBIO-SCIENTIFIC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALERS.PA.


What is EUROBIO-SCIENTIFIC worth?

EUROBIO-SCIENTIFIC (ALERS.PA) has a market capitalization of 248.05M EUR. This makes ALERS.PA a Micro Cap stock.


ALERS.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALERS.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA. While ALERS.PA has a great health rating, its profitability is only average at the moment.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALERS.PA Financial Highlights

Over the last trailing twelve months ALERS.PA reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS decreased by -63.15% compared to the year before.


Industry RankSector Rank
PM (TTM) 1.46%
ROA 0.91%
ROE 1.3%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%-41.15%
Sales Q2Q%10.27%
EPS 1Y (TTM)-63.15%
Revenue 1Y (TTM)12.47%

ALERS.PA Forecast & Estimates

9 analysts have analysed ALERS.PA and the average price target is 30.6 EUR. This implies a price increase of 26.45% is expected in the next year compared to the current price of 24.2.

For the next year, analysts expect an EPS growth of -11.36% and a revenue growth 22.03% for ALERS.PA


Analysts
Analysts84.44
Price Target30.6 (26.45%)
EPS Next Y-11.36%
Revenue Next Year22.03%

ALERS.PA Ownership

Ownership
Inst Owners2.86%
Ins Owners0.04%
Short Float %N/A
Short RatioN/A